Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus schedules in recurrent/metastatic breast cancer
NCT00255788Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2005
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in breast cancer (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Response rate by clinical evaluation and radiologic reevaluation at 8 weeks and Early progression rate by clinical evaluation and radiologic reevaluation at 8 weeks. Started May 2005; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00255788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255788.